Microglial complement receptor 3 regulates brain Aβ levels through secreted proteolytic activity
Open accessThe DOI matches its Crossref record; 68 of the 71 references it cites were found in a registry or an index.
Abstract
Recent genetic evidence supports a link between microglia and the complement system in Alzheimer's disease (AD). In this study, we uncovered a novel role for the microglial complement receptor 3 (CR3) in the regulation of soluble β-amyloid (Aβ) clearance independent of phagocytosis. Unexpectedly, ablation of CR3 in human amyloid precursor protein-transgenic mice results in decreased, rather than increased, Aβ accumulation. In line with these findings, cultured microglia lacking CR3 are more efficient than wild-type cells at degrading extracellular Aβ by secreting enzymatic factors, including tissue plasminogen activator. Furthermore, a small molecule modulator of CR3 reduces soluble Aβ levels and Aβ half-life in brain interstitial fluid (ISF), as measured by in vivo microdialysis. These results suggest that CR3 limits Aβ clearance from the ISF, illustrating a novel role for CR3 and microglia in brain Aβ metabolism and defining a potential new therapeutic target in AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Conversely, fibrinogen/CD11b signaling may enhance Aβ-induced neurodegeneration by suppressing Aβ clearance (Czirr et al., 2017).”
From Fibrinogen induces microglia-mediated spine elimination and cognitive impairment in an Alzheimer's disease model (2019) · cites this paper as Czirr et al., 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although CR3 mediates the clearance of fibrillar and oligomeric Aβ, it might also promote the accumulation of Aβ deposits [144, 145].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [144]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Further, studies manipulating the complement system have yielded mixed results.”
The cited source says what the claim attributes to it.
In the citing paper
“The deficiency of complement factors such as C1q, C3, C3ar1, C5aR, and Cd59, has exacerbated neuropathology in some studies [84–86] and reduced neuropathology in others [87–89].”
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Aβ plaque burden was decreased in the hippocampus of 5XFAD:Fggγ390–396A mice (Figure 4B).”
From Fibrinogen induces microglia-mediated spine elimination and cognitive impairment in an Alzheimer's disease model (2019) · cites this paper as Czirr et al., 2017
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Microglia Sculpt Postnatal Neural Circuits in an Activity and Complement-Dependent Manner
Schafer, D. P., Lehrman, E. K., Kautzman, A. G., Koyama, R., Mardinly, A. R., Yamasaki, R., Ransohoff, R. M., Greenberg, M. E., Barres, B. A., & Stevens, B. (2012) · Neuron · doi:10.1016/j.neuron.2012.03.026 · Cited by 4,089 · cited 2×
“, 2012), as well as the removal of synapses during development (Stevens et al., 2007; Schafer et al., 2012), in a model of neurodegeneration (Stevens et al.”
BackgroundComplement and microglia mediate early synapse loss in Alzheimer mouse models
Hong, S., Beja-Glasser, V. F., Nfonoyim, B. M., Frouin, A., Li, S., Ramakrishnan, S., Merry, K. M., Shi, Q., Rosenthal, A., Barres, B. A., et al. (2016) · Science · doi:10.1126/science.aad8373 · Cited by 3,343
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
The Classical Complement Cascade Mediates CNS Synapse Elimination
Stevens, B., Allen, N. J., Vazquez, L. E., Howell, G. R., Christopherson, K. S., Nouri, N., Micheva, K. D., Mehalow, A. K., Huberman, A. D., Stafford, B., et al. (2007) · Cell · doi:10.1016/j.cell.2007.10.036 · Cited by 3,313 · cited 3×
“, 2012), in a model of neurodegeneration (Stevens et al., 2007) and in amyloid precursor protein (APP)–transgenic mice (Hong et al.”
BackgroundTREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020 · cited 1×
“…genetic support from genome-wide association studies that have identified several single nucleotide polymorphisms in immune-related genes that increase the risk of developing late onset AD (Lambert et al., 2009; Jun et al., 2010; Naj et al., 2011; Guerreiro et al., 2013; Jonsson et al., 2013).”
BackgroundVariant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558 · cited 2×
“This notion has received genetic support from genome-wide association studies that have identified several single nucleotide polymorphisms in immune-related genes that increase the risk of developing late onset AD (Lambert et al., 2009; Jun et al., 2010; Naj et al., 2011; Guerreiro et al., 2013; Jonsson et al., 2013).”
BackgroundResultGenome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease
the European Alzheimer's Disease Initiative Investigators, Lambert, J.-C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.439 · Cited by 2,234
Naj, A. C., Jun, G., Beecham, G. W., Wang, L.-S., Vardarajan, B. N., Buros, J., Gallins, P. J., Buxbaum, J. D., Jarvik, G. P., Crane, P. K., et al. (2011) · Nature Genetics · doi:10.1038/ng.801 · Cited by 1,901 · cited 2×
“This notion has received genetic support from genome-wide association studies that have identified several single nucleotide polymorphisms in immune-related genes that increase the risk of developing late onset AD (Lambert et al., 2009; Jun et al., 2010; Naj et al., 2011; Guerreiro et al., 2013; Jonsson et al., 2013).”
BackgroundResultJankowsky, J. L., Fadale, D. J., Anderson, J., Xu, G. M., Gonzales, V., Jenkins, N. A., Copeland, N. G., Lee, M. K., Younkin, L. H., Wagner, S. L., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh019 · Cited by 1,575
Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance
Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., Fagan, A. M., Morris, J. C., Mawuenyega, K. G., Cruchaga, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002156 · Cited by 1,242 · cited 2×
“In vivo microdialysis was performed as previously described (Cirrito et al., 2003; Castellano et al., 2011).”
MethodMicroglial cell origin and phenotypes in health and disease
Saijo, K., & Glass, C. K. (2011) · Nature Reviews Immunology · doi:10.1038/nri3086 · Cited by 1,100 · cited 1×
“Indeed, microglia are now widely recognized to have important roles in neurodegeneration and in AD (Saijo and Glass, 2011).”
BackgroundApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models
Cramer, P. E., Cirrito, J. R., Wesson, D. W., Lee, C. Y. D., Karlo, J. C., Zinn, A. E., Casali, B. T., Restivo, J. L., Goebel, W. D., James, M. J., et al. (2012) · Science · doi:10.1126/science.1217697 · Cited by 1,050 · cited 2×
“, 2004), which are routinely used for in vivo microdialysis (Yan et al., 2009; Cramer et al., 2012; Kraft et al., 2013) at an age before”
BackgroundMethodSelf-citationClassification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins
Ray, S., Britschgi, M., Herbert, C., Takeda-Uchimura, Y., Boxer, A., Blennow, K., Friedman, L. F., Galasko, D. R., Jutel, M., Karydas, A., et al. (2007) · Nature Medicine · doi:10.1038/nm1653 · Cited by 1,048
Self-citationRapid appearance and local toxicity of amyloid-β plaques in a mouse model of Alzheimer’s disease
Meyer-Luehmann, M., Spires-Jones, T. L., Prada, C., Garcia-Alloza, M., de Calignon, A., Rozkalne, A., Koenigsknecht-Talboo, J., Holtzman, D. M., Bacskai, B. J., & Hyman, B. T. (2008) · Nature · doi:10.1038/nature06616 · Cited by 987 · cited 2×
“Although microglia are able to take up fibrillar Aβ into endosome-like compartments (Frackowiak et al., 1992; Meyer-Luehmann et al., 2008), they seem inefficient at degrading and removing Aβ deposits from the AD brain (Grathwohl et al., 2009).”
BackgroundMetabolic Regulation of Brain Aβ by Neprilysin
Iwata, N., Tsubuki, S., Takaki, Y., Shirotani, K., Lu, B., Gerard, N. P., Gerard, C., Hama, E., Lee, H.-J., & Saido, T. C. (2001) · Science · doi:10.1126/science.1059946 · Cited by 961 · cited 2×
“1086 Aβ degradation in the extracellular space can be accomplished by several enzymes, and published studies have mainly focused on the proteases neprilysin, insulysin (insulin-degrading enzyme), MMP2, MMP9, and tPA/plasmin (Iwata et al., 2001; Melchor et al., 2003; Song and Hersh, 2005; Eckman et al., 2006; Yan et al…”
BackgroundImmune activation in brain aging and neurodegeneration: too much or too little?
Lucin, K. M., & Wyss-Coray, T. (2009) · Neuron · doi:10.1016/j.neuron.2009.08.039 · Cited by 679 · cited 1×
“Removal of Aβ deposits is, in part, mediated through phagocytic cells in concert with immune recognition molecules (Lucin and Wyss-Coray, 2009; Czirr and Wyss-Coray, 2012).”
BackgroundSelf-citationExcitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator
Tsirka, S. E., Gualandris, A., Amaral, D. G., & Strickland, S. (1995) · Nature · doi:10.1038/377340a0 · Cited by 663 · cited 2×
“…less efficient at degrading Aβ injected in the hippocampus (Melchor et al., 2003), but the function of tPA in microglia remains poorly understood (Tsirka et al., 1995; Gravanis and Tsirka, 2005). tPA mRNA levels were unchanged between acutely isolated primary adult microglia-like cells from APP…”
BackgroundHuman amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo
Bateman, R. J., Munsell, L. Y., Morris, J. C., Swarm, R., Yarasheski, K. E., & Holtzman, D. M. (2006) · Nature Medicine · doi:10.1038/nm1438 · Cited by 599 · cited 1×
“However, evidence indicates that impaired clearance is mainly responsible (Bateman et al., 2006; Roberts et al., 2014).”
BackgroundRamos-DeSimone, N., Hahn-Dantona, E., Sipley, J., Nagase, H., French, D. L., & Quigley, J. P. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.19.13066 · Cited by 591 · cited 1×
“It can activate both plasminogen and MMPs and, therefore, mediate Aβ degradation via different pathways (Hahn-Dantona et al., 1999; Ramos-DeSimone et al., 1999).”
BackgroundA Cell Surface Receptor Complex for Fibrillar β-Amyloid Mediates Microglial Activation
Bamberger, M. E., Harris, M. E., McDonald, D. R., Husemann, J., & Landreth, G. E. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-07-02665.2003 · Cited by 501 · cited 1×
“It has been suggested that the proinflammatory environment of the AD brain might make them less efficient phagocytes (Bamberger et al., 2003; Koenigsknecht-Talboo and Landreth, 2005).”
BackgroundKoenigsknecht-Talboo, J., & Landreth, G. E. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1808-05.2005 · Cited by 477 · cited 1×
“It has been suggested that the proinflammatory environment of the AD brain might make them less efficient phagocytes (Bamberger et al., 2003; Koenigsknecht-Talboo and Landreth, 2005).”
BackgroundSu, E. J., Fredriksson, L., Geyer, M., Folestad, E., Cale, J., Andrae, J., Gao, Y., Pietras, K., Mann, K., Yepes, M., et al. (2008) · Nature Medicine · doi:10.1038/nm1787 · Cited by 468
Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice
Wyss-Coray, T., Yan, F., Lin, A. H.-T., Lambris, J. D., Alexander, J. J., Quigg, R. J., & Masliah, E. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162350199 · Cited by 446 · cited 1×
“Complement proteins are important for removal of Aβ deposits, and interference with the central component C3 results in increased plaque deposition (Wyss-Coray et al., 2002; Maier et al., 2008).”
BackgroundSelf-citationJun, G. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.201 · Cited by 422 · cited 1×
“…genetic support from genome-wide association studies that have identified several single nucleotide polymorphisms in immune-related genes that increase the risk of developing late onset AD (Lambert et al., 2009; Jun et al., 2010; Naj et al., 2011; Guerreiro et al., 2013; Jonsson et al., 2013).”
BackgroundMicroglia Mediate the Clearance of Soluble Aβ through Fluid Phase Macropinocytosis
Mandrekar, S., Jiang, Q., Lee, C. Y. D., Koenigsknecht-Talboo, J., Holtzman, D. M., & Landreth, G. E. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5572-08.2009 · Cited by 415 · cited 1×
“There is also evidence that microglia internalize and degrade soluble Aβ in lysosomes through fluid-phase macropinocytosis (Mandrekar et al., 2009) or through the secretion of various Aβ-degrading activities.”
BackgroundRyu, J. K., & McLarnon, J. G. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00434.x · Cited by 406
Self-citationFormation and maintenance of Alzheimer's disease β-amyloid plaques in the absence of microglia
Grathwohl, S. A., Kälin, R. E., Bolmont, T., Prokop, S., Winkelmann, G., Kaeser, S. A., Odenthal, J., Radde, R., Eldh, T., Gandy, S., et al. (2009) · Nature Neuroscience · doi:10.1038/nn.2432 · Cited by 401 · cited 2×
“, 2008), they seem inefficient at degrading and removing Aβ deposits from the AD brain (Grathwohl et al., 2009).”
BackgroundCirrito, J. R., May, P. C., O'Dell, M. A., Taylor, J. W., Parsadanian, M., Cramer, J. W., Audia, J. E., Nissen, J. S., Bales, K. R., Paul, S. M., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-26-08844.2003 · Cited by 394 · cited 2×
“In vivo microdialysis was performed as previously described (Cirrito et al., 2003; Castellano et al., 2011).”
MethodSelf-citationMatrix Metalloproteinase-9 Degrades Amyloid-β Fibrils in Vitro and Compact Plaques in Situ
Yan, P., Hu, X., Song, H., Yin, K., Bateman, R. J., Cirrito, J. R., Xiao, Q., Hsu, F. F., Turk, J. W., Xu, J., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602440200 · Cited by 380 · cited 3×
“EDTA is a strong inhibitor of metalloproteinases, and matrix metalloproteinase 2 (MMP2) and MMP9 have previously been implicated as major Aβ-degrading enzymes (Yan et al., 2006; Hernandez-Guillamon et al., 2010).”
BackgroundSelf-citationCirrito, J. R., Disabato, B. M., Restivo, J. L., Verges, D. K., Goebel, W. D., Sathyan, A., Hayreh, D., D'Angelo, G., Benzinger, T., Yoon, H., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1107411108 · Cited by 377 · cited 1×
“Quantitative measurements of Aβ collected from in vivo microdialysis fractions were performed by sandwich ELI SA, as previously described (Cirrito et al., 2011).”
MethodAttenuating astrocyte activation accelerates plaque pathogenesis in APP/PS1 mice
Kraft, A. W., Hu, X., Yoon, H., Yan, P., Xiao, Q., Wang, Y., Gil, S. C., Brown, J., Wilhelmsson, U., Restivo, J. L., et al. (2013) · The FASEB Journal · doi:10.1096/fj.12-208660 · Cited by 355 · cited 2×
“, 2004), which are routinely used for in vivo microdialysis (Yan et al., 2009; Cramer et al., 2012; Kraft et al., 2013) at an age before”
BackgroundMethodSavonenko, A., Xu, G. M., Melnikova, T., Morton, J. L., Gonzales, V., Wong, M. P. F., Price, D. L., Tang, F., Markowska, A. L., & Borchelt, D. R. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.10.022 · Cited by 346 · cited 1×
“MAterIAlS And MethodS transgenic mice T41 APP-transgenic mice (mThy-1-hAPP751V171I,KM670/671NL), CR3-deficient mice (Itgamtm1Myd+/−), and APP/PS1+/− (mPrP-hAPPKM670/671NL PS1-ΔExon9) mice have been described previously (Soriano et al., 1999; Rockenstein et al., 2001; Savonenko et al., 2005).”
BackgroundUp-Regulated Production and Activation of the Complement System in Alzheimer's Disease Brain
Yasojima, K., Schwab, C., McGeer, E. G., & McGeer, P. L. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65340-0 · Cited by 327 · cited 2×
“reSultS Genetic ablation of cr3 in APP-transgenic mice leads to reduced Aβ deposition Human AD brains show an increase in complement proteins associated with plaques (Afagh et al., 1996; Yasojima et al., 1999).”
BackgroundMaier, M., Peng, Y., Jiang, L., Seabrook, T. J., Carroll, M. C., & Lemere, C. A. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.0829-08.2008 · Cited by 323 · cited 1×
“Complement proteins are important for removal of Aβ deposits, and interference with the central component C3 results in increased plaque deposition (Wyss-Coray et al., 2002; Maier et al., 2008).”
BackgroundCR3: a general purpose adhesion-recognition receptor essential for innate immunity
Ehlers, M. R. W. (2000) · Microbes and Infection · doi:10.1016/s1286-4579(00)00299-9 · Cited by 323 · cited 1×
“Complement receptor 3 (CR3; CR3, CD11b/CD18, and Mac-1) is one of the major phagocytic receptors expressed on microglia (Ehlers, 2000) and is a dimeric receptor comprised of CD18 and its unique subunit CD11b (Ivashkiv, 2009; Linnartz and Neumann, 2013).”
BackgroundSisodia, S., Koo, E., Hoffman, P., Perry, G., & Price, D. (1993) · The Journal of Neuroscience · doi:10.1523/jneurosci.13-07-03136.1993 · Cited by 284 · cited 2×
“The following antibodies were used: CT15 (Sisodia et al., 1993), β-actin (Sigma-Aldrich), neuron-specific enolase (5E2; Thermo Fisher Scientific), and IC16 (Hahn et al.”
MethodWeggen, S., Eriksen, J. L., Sagi, S. A., Pietrzik, C. U., Ozols, V., Fauq, A., Golde, T. E., & Koo, E. H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303592200 · Cited by 280
Frackowiak, J., Wisniewski, H. M., Wegiel, J., Merz, G. S., Iqbal, K., & Wang, K. C. (1992) · Acta Neuropathologica · doi:10.1007/bf00227813 · Cited by 276 · cited 2×
“Although microglia are able to take up fibrillar Aβ into endosome-like compartments (Frackowiak et al., 1992; Meyer-Luehmann et al., 2008), they seem inefficient at degrading and removing Aβ deposits from the AD brain (Grathwohl et al., 2009).”
BackgroundCharacterizing the Appearance and Growth of Amyloid Plaques in APP/PS1 Mice
Yan, P., Bero, A. W., Cirrito, J. R., Xiao, Q., Hu, X., Wang, Y., Gonzales, E., Holtzman, D. M., & Lee, J.-M. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.2637-09.2009 · Cited by 264 · cited 2×
“, 2004), which are routinely used for in vivo microdialysis (Yan et al., 2009; Cramer et al., 2012; Kraft et al., 2013) at an age before”
BackgroundMethodSelf-citationAmyloid‐β efflux from the central nervous system into the plasma
Roberts, K. F., Elbert, D. L., Kasten, T. P., Patterson, B. W., Sigurdson, W. C., Connors, R. E., Ovod, V., Munsell, L. Y., Mawuenyega, K. G., Miller‐Thomas, M. M., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24270 · Cited by 254 · cited 1×
“However, evidence indicates that impaired clearance is mainly responsible (Bateman et al., 2006; Roberts et al., 2014).”
BackgroundLocalization and Cell Association of C1q in Alzheimer's Disease Brain
Afagh, A., Cummings, B. J., Cribbs, D. H., Cotman, C. W., & Tenner, A. J. (1996) · Experimental Neurology · doi:10.1006/exnr.1996.0043 · Cited by 224 · cited 2×
“reSultS Genetic ablation of cr3 in APP-transgenic mice leads to reduced Aβ deposition Human AD brains show an increase in complement proteins associated with plaques (Afagh et al., 1996; Yasojima et al., 1999).”
BackgroundRockenstein, E., Mallory, M., Mante, M., Sisk, A., & Masliaha, E. (2001) · Journal of Neuroscience Research · doi:10.1002/jnr.1247 · Cited by 223
Fibrinogen is associated with an increased risk of Alzheimer disease and vascular dementia
van Oijen, M., Witteman, J. C., Hofman, A., Koudstaal, P. J., & Breteler, M. M. B. (2005) · Stroke · doi:10.1161/01.str.0000189721.31432.26 · Cited by 222 · cited 1×
“Interestingly, levels of natural CR3 ligands, such as complement fragments, ICAM-1, and fibrin, are increased in AD patients (Shen et al., 2001; van Oijen et al., 2005; Ray et recent genetic evidence supports a link between microglia and the complement system in Alzheimer’s disease (Ad).”
BackgroundMice Deficient in Mac-1 (CD11b/CD18) Are Less Susceptible to Cerebral Ischemia/Reperfusion Injury
Soriano, S. G., Coxon, A., Wang, Y. F., Frosch, M. P., Lipton, S. A., Hickey, P. R., & Mayadas, T. N. (1999) · Stroke · doi:10.1161/01.str.30.1.134 · Cited by 216
Cross-regulation of signaling by ITAM-associated receptors
Ivashkiv, L. B. (2009) · Nature Immunology · doi:10.1038/ni.1706 · Cited by 215 · cited 1×
“Complement receptor 3 (CR3; CR3, CD11b/CD18, and Mac-1) is one of the major phagocytic receptors expressed on microglia (Ehlers, 2000) and is a dimeric receptor comprised of CD18 and its unique subunit CD11b (Ivashkiv, 2009; Linnartz and Neumann, 2013).”
BackgroundThe immunology of neurodegeneration
Czirr, E., & Wyss-Coray, T. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58656 · Cited by 213 · cited 1×
“Removal of Aβ deposits is, in part, mediated through phagocytic cells in concert with immune recognition molecules (Lucin and Wyss-Coray, 2009; Czirr and Wyss-Coray, 2012).”
BackgroundMelchor, J. P., Pawlak, R., & Strickland, S. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-26-08867.2003 · Cited by 202 · cited 7×
“1086 Aβ degradation in the extracellular space can be accomplished by several enzymes, and published studies have mainly focused on the proteases neprilysin, insulysin (insulin-degrading enzyme), MMP2, MMP9, and tPA/plasmin (Iwata et al., 2001; Melchor et al., 2003; Song and Hersh, 2005; Eckman et al., 2006; Yan et al…”
BackgroundInfluentialEckman, E. A., Adams, S. K., Troendle, F. J., Stodola, B. A., Kahn, M. A., Fauq, A. H., Xiao, H. D., Bernstein, K. E., & Eckman, C. B. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605827200 · Cited by 196 · cited 2×
“1086 Aβ degradation in the extracellular space can be accomplished by several enzymes, and published studies have mainly focused on the proteases neprilysin, insulysin (insulin-degrading enzyme), MMP2, MMP9, and tPA/plasmin (Iwata et al., 2001; Melchor et al., 2003; Song and Hersh, 2005; Eckman et al., 2006; Yan et al…”
BackgroundComplement activation by neurofibrillary tangles in Alzheimer's disease
Shen, Y., Lue, L.-F., Yang, L.-B., Roher, A., Kuo, Y.-M., Strohmeyer, R., Goux, W. J., Lee, V., Johnson, G. V. W., Webster, S. D., et al. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)01842-0 · Cited by 185 · cited 1×
“Interestingly, levels of natural CR3 ligands, such as complement fragments, ICAM-1, and fibrin, are increased in AD patients (Shen et al., 2001; van Oijen et al., 2005; Ray et recent genetic evidence supports a link between microglia and the complement system in Alzheimer’s disease (Ad).”
BackgroundFu, H., Liu, B., Frost, J. L., Hong, S., Jin, M., Ostaszewski, B., Shankar, G. M., Costantino, I. M., Carroll, M. C., Mayadas, T. N., et al. (2012) · Glia · doi:10.1002/glia.22331 · Cited by 180 · cited 3×
“In agreement with published data (Fu et al., 2012), we found a significant decrease in baseline phagocytosis (Fig.”
BackgroundResultQiu, W. Q., Ye, Z., Kholodenko, D., Seubert, P., & Selkoe, D. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.10.6641 · Cited by 177
Small Molecule–Mediated Activation of the Integrin CD11b/CD18 Reduces Inflammatory Disease
Maiguel, D., Faridi, M. H., Wei, C., Kuwano, Y., Balla, K. M., Hernandez, D., Barth, C. J., Lugo, G., Donnelly, M., Nayer, A., et al. (2011) · Science Signaling · doi:10.1126/scisignal.2001811 · Cited by 130 · cited 4×
“It has been used to anchor CR3-expressing cells in place and prevent infiltration of proinflammatory monocytes after injury in peripheral organs (Maiguel et al., 2011; Jagarapu et al., 2015).”
BackgroundMethodInfluentialSachs, B. D., Baillie, G. S., McCall, J. R., Passino, M. A., Schachtrup, C., Wallace, D. A., Dunlop, A. J., MacKenzie, K. F., Klussmann, E., Lynch, M. J., et al. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200701040 · Cited by 126 · cited 2×
“tPA zymography and active tPA measurements Hippocampal tPA activity was measured by in situ zymography with casein substrate, as previously described (Sachs et al., 2007).”
MethodLinnartz, B., & Neumann, H. (2013) · Glia · doi:10.1002/glia.22359 · Cited by 116 · cited 15×
“The antibodies used were: CD11b-PE antibody (BioLegend), CD162–Alexa Fluor 647 (BD), CD62L-FITC and CD18-PE (eBioscience), and CD54APC, CD14-Pe/Cy7, CD49d-FITC, CD11a-PE, CD11b– eFluor 450 (all BioLegend).”
BackgroundInfluentialHahn-Dantona, E. A., RAMOS‐DeSIMONE, N., Sipley, J. D., Nagase, H., French, D. L., & Quigley, J. P. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb07696.x · Cited by 100 · cited 1×
“It can activate both plasminogen and MMPs and, therefore, mediate Aβ degradation via different pathways (Hahn-Dantona et al., 1999; Ramos-DeSimone et al., 1999).”
BackgroundCerebrospinal fluid levels of complement proteins C3, C4 and CR1 in Alzheimer’s disease
Daborg, J., Andréasson, U., Pekna, M., Lautner, R., Hanse, E., Minthon, L., Blennow, K., Hansson, O., & Zetterberg, H. (2012) · Journal of Neural Transmission · doi:10.1007/s00702-012-0797-8 · Cited by 97 · cited 1×
“…December 2, 2019jem.rupress.org Downloaded from http://doi.org/10.1084/jem.20162011Published Online: 15 March, 2017 | Supp Info: Complement receptor 3 regulates brain Aβ turnover | Czirr et al.1082 al., 2007; Xu et al., 2008; Ryu and McLarnon, 2009; Daborg et al., 2012; Bardehle et al., 2015).”
BackgroundInfluentialXu, G., Zhang, H., Zhang, S., Fan, X., & Liu, X. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01268.x · Cited by 89 · cited 1×
“…December 2, 2019jem.rupress.org Downloaded from http://doi.org/10.1084/jem.20162011Published Online: 15 March, 2017 | Supp Info: Complement receptor 3 regulates brain Aβ turnover | Czirr et al.1082 al., 2007; Xu et al., 2008; Ryu and McLarnon, 2009; Daborg et al., 2012; Bardehle et al., 2015).”
BackgroundInfluentialBreaking boundaries—coagulation and fibrinolysis at the neurovascular interface
Bardehle, S., Rafalski, V. A., & Akassoglou, K. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00354 · Cited by 76 · cited 1×
“…December 2, 2019jem.rupress.org Downloaded from http://doi.org/10.1084/jem.20162011Published Online: 15 March, 2017 | Supp Info: Complement receptor 3 regulates brain Aβ turnover | Czirr et al.1082 al., 2007; Xu et al., 2008; Ryu and McLarnon, 2009; Daborg et al., 2012; Bardehle et al., 2015).”
BackgroundInfluentialSelf-citationTissue plasminogen activator and glial function
Gravanis, I., & Tsirka, S. E. (2004) · Glia · doi:10.1002/glia.20115 · Cited by 57 · cited 1×
“…degrading Aβ injected in the hippocampus (Melchor et al., 2003), but the function of tPA in microglia remains poorly understood (Tsirka et al., 1995; Gravanis and Tsirka, 2005). tPA mRNA levels were unchanged between acutely isolated primary adult microglia-like cells from APP and APP/CR3−/− mice…”
BackgroundHernandez-Guillamon, M., Mawhirt, S., Fossati, S., Blais, S., Pares, M., Penalba, A., Boada, M., Couraud, P.-O., Neubert, T. A., Montaner, J., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.135228 · Cited by 48 · cited 3×
“EDTA is a strong inhibitor of metalloproteinases, and matrix metalloproteinase 2 (MMP2) and MMP9 have previously been implicated as major Aβ-degrading enzymes (Yan et al., 2006; Hernandez-Guillamon et al., 2010).”
BackgroundComplement Receptor 3 Influences Toll-like Receptor 7/8-Dependent Inflammation
Reed, J. H., Jain, M. K., Lee, K., Kandimalla, E. R., Faridi, M. H., Buyon, J. P., Gupta, V., & Clancy, R. M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.403303 · Cited by 47
Faridi, M. H., Altintas, M. M., Gomez, C. A., Duque, J. C., Vázquez-Padrón, R. I., & Gupta, V. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.02.018 · Cited by 44 · cited 15×
“The antibodies used were: CD11b-PE antibody (BioLegend), CD162–Alexa Fluor 647 (BD), CD62L-FITC and CD18-PE (eBioscience), and CD54APC, CD14-Pe/Cy7, CD49d-FITC, CD11a-PE, CD11b– eFluor 450 (all BioLegend).”
BackgroundInfluentialHahn, S., Brüning, T., Ness, J., Czirr, E., Baches, S., Gijsen, H., Korth, C., Pietrzik, C. U., Bulic, B., & Weggen, S. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.07118.x · Cited by 42 · cited 2×
“, 1993), β-actin (Sigma-Aldrich), neuron-specific enolase (5E2; Thermo Fisher Scientific), and IC16 (Hahn et al., 2011).”
MethodEfficacy of Leukadherin-1 in the Prevention of Hyperoxia-Induced Lung Injury in Neonatal Rats
Jagarapu, J., Kelchtermans, J., Rong, M., Chen, S., Hehre, D., Hummler, S. C., Faridi, M. H., Gupta, V., & WU, S. M. (2015) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2014-0422oc · Cited by 36 · cited 2×
“It has been used to anchor CR3-expressing cells in place and prevent infiltration of proinflammatory monocytes after injury in peripheral organs (Maiguel et al., 2011; Jagarapu et al., 2015).”
MethodInsulysin: An Allosteric Enzyme As a Target for Alzheimer's Disease
Song, E. S., & Hersh, L. B. (2005) · Journal of Molecular Neuroscience · doi:10.1385/jmn:25:3:201 · Cited by 34 · cited 1×
“1086 Aβ degradation in the extracellular space can be accomplished by several enzymes, and published studies have mainly focused on the proteases neprilysin, insulysin (insulin-degrading enzyme), MMP2, MMP9, and tPA/plasmin (Iwata et al., 2001; Melchor et al., 2003; Song and Hersh, 2005; Eckman et al., 2006; Yan et al…”
BackgroundRoberts, A. L., Fürnrohr, B., Vyse, T., & Rhodes, B. (2016) · Clinical and Experimental Immunology · doi:10.1111/cei.12803 · Cited by 19 · cited 1×
“There is evidence from studies in human PBMC–derived macrophages, human monocyte cell lines (Reed et al., 2013), and in human NK cells (Roberts et al., 2016) that LA-1 treatment can affect key transcription factors, e.g., MyD88, to modulate secretion of cytokines.”
Background
Cited by
Microglia in Alzheimer’s disease
Hansen, D. V., Hanson, J. E., & Sheng, M. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201709069 · Cited by 1,935
“…molecules in the brain, is present in Aβ plaques (Namba et al., 1991; Wisniewski and Frangione, 1992; Zhan et al., 1995) and contributes to both the clearance and the amyloid deposition of Aβ peptide (Bales et al., 1997a; DeMattos et al., 2004; Bien-Ly et al., 2012; Holtzman et al., 2012).”
BackgroundTissue macrophages: heterogeneity and functions
Gordon, S., & Plüddemann, A. (2017) · BMC Biology · doi:10.1186/s12915-017-0392-4 · Cited by 603
Inflammation: the link between comorbidities, genetics, and Alzheimer’s disease
Newcombe, E. A., Camats-Perna, J., Silva, M. L., Valmas, N., Huat, T. J., & Medeiros, R. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1313-3 · Cited by 532
Litvinchuk, A., Wan, Y.-W., Swartzlander, D. B., Chen, F., Cole, A., Propson, N. E., Wang, Q., Zhang, B., Liu, Z., & Zheng, H. (2018) · Neuron · doi:10.1016/j.neuron.2018.10.031 · Cited by 523
“Through an independent mechanism involving extracellular secretase activity, CR3 is shown to regulate Ab degradation (Czirr et al., 2017).”
Microglia and Astrocytes in Alzheimer's Disease: Implications for Therapy
Fakhoury, M. (2018) · Current Neuropharmacology · doi:10.2174/1570159x15666170720095240 · Cited by 479
“aad8373] [PMID: 27033548] [50] Czirr, E.”
Background
Metadata
- Authors
- Czirr, E., Castello, N. A., Mosher, K. I., Castellano, J. M., Hinkson, I. V., Lucin, K. M., Baeza-Raja, B., Ryu, J. K., Li, L., Farina, S. N., Belichenko, N. P., Longo, F. M., Akassoglou, K., Britschgi, M., Cirrito, J. R., & Wyss-Coray, T.
- Affiliations
- Stanford Medicine (US)
- University of California, San Francisco (US)
- VA Palo Alto Health Care System (US)
- Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305 1
- Washington University in St. Louis (US)
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2017-03-15
- Volume
- 214
- Issue
- 4
- Pages
- 1081-1092
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC5379986
- OpenAlex
- W2596986005
- Cited by
- 126
- References
- 71
- Citations by year
- 2026: 5 · 2025: 12 · 2024: 26 · 2023: 20 · 2022: 9 · 2021: 16 · 2020: 17 · 2019: 9 · 2018: 7 · 2017: 5
- FWCI
- 7.69
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by-nc-sa)
- Funders
- Alexander von Humboldt Foundation
- Jane Coffin Childs Memorial Fund for Medical Research
- National Institute of Neurological Disorders and Stroke (P01 NS074969)
- National Institutes of Health
- National Institute on Aging (R01 AG042513, AG045034)
- Department of Veterans Affairs
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Keywords
- microglia, complement receptor 3, CD11b/CD18, Alzheimer's disease, amyloid clearance, tissue plasminogen activator, proteolytic activity, amyloid precursor protein transgenic mice, brain interstitial fluid, complement system, small molecule modulators, therapeutic target
- MeSH terms
- Alzheimer Disease, Animals, Benzoates, Brain, Mice, Inbred C57BL, Thiohydantoins, Macrophage-1 Antigen, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Microglia, Mice, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.